Everolimus improves progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung, gastrointestinal tract
MD Anderson led research in field, from small investigator-initiated studies to international confirmatory trials
MD Anderson News Release 09/26/2015
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal...
Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
CheckMate-025 study led by 鶹ӳ MD Anderson Cancer Center portends paradigm change in standard of care treatment...
MD Anderson study identifies leukemia tumor suppressor
Protein-coding gene hnRNP K may be culprit in acute myeloid leukemia
MD Anderson News Release 09/24/2015
A protein-coding...
A Conversation With a Living Legend® returns to San Antonio to honor Emmitt Smith
Football legend teams up with MD Anderson to support cancer research
MD Anderson News Release 09/22/2015
鶹ӳ MD Anderson Cancer Center heads to San Antonio Oct. 13 for the sixth annual A Conversation With a Living Legend® honoring Pro Football Hall of Fame member and “Dancing with the Stars” champion Emmitt Smith.
The luncheon and program will be held at the Marriott Rivercenter, 101...
MD Anderson immunologist Jim Allison wins Lasker-DeBakey Award
Cancer immunotherapy pioneer awarded prestigious U.S. medical research honor
MD Anderson News Release 09/08/2015
For inventing...
MD Anderson brings Making Cancer History® seminar to Atlanta
Free event offers information on the latest cancer treatment and prevention strategies
MD Anderson News Release 09/03/2015...
MD Anderson to honor Houstonians for their efforts to end cancer
River Oaks Country Club event to pay tribute to Houston community
MD Anderson News Release 09/02/2015
The University...